Ashland Global vs Ecolab: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Ashland Global Holdings Inc (ASH)

Q3 202628 Jul – 25 Sep 2026

▲3

Ashland's sale process advances as buyback and new product offset weak additives

Takeover bids now being collected Ashland is collecting takeover bids this month, with Apollo, Carlyle and others interested. Activist pressure has pushed the company toward a possible sale, and reports suggest a deal could value shares well above recent levels. This keeps a buyout premium in the stock.
The sale process is the biggest force behind ASH's price right now, directly tied to activist pressure and reported bid interest.
New $1 billion buyback doubles prior plan Ashland announced a new $1 billion share repurchase plan, twice its previous authorization. Buying back stock can support the share price by reducing the number of shares and signaling management's confidence, even as the stock had slipped recently.
The buyback is a fresh capital-return action that directly supports the stock price and shows management's response to recent weakness.
New oral biologics ingredient launched Ashland launched Permexa sodium caprate, an ingredient that helps turn injectable drugs into pills, targeting the fast-growing GLP-1 and metabolic markets. Partners are already testing it. If it wins commercial contracts, it could add a new long-term growth stream.
This is a new product that could drive future revenue growth in Ashland's strongest division, Life Sciences.
Solid sales but profit pressure persists Third-quarter sales rose 7% to $497 million and full-year guidance was reaffirmed, but adjusted EBITDA fell 4% and EPS growth outlook was trimmed due to higher taxes and costs. Weak Specialty Additives and Intermediates continue to weigh on overall profitability.
This explains the underlying business performance that both supports and limits the stock, balancing the positive sale and buyback news.

August 202628 Jul – 25 Sep 2026

▲3

Ashland's sale process advances as buyback and new product offset weak additives

Takeover bids now being collected Ashland is collecting takeover bids this month, with Apollo, Carlyle and others interested. Activist pressure has pushed the company toward a possible sale, and reports suggest a deal could value shares well above recent levels. This keeps a buyout premium in the stock.
The sale process is the biggest force behind ASH's price right now, directly tied to activist pressure and reported bid interest.
New $1 billion buyback doubles prior plan Ashland announced a new $1 billion share repurchase plan, twice its previous authorization. Buying back stock can support the share price by reducing the number of shares and signaling management's confidence, even as the stock had slipped recently.
The buyback is a fresh capital-return action that directly supports the stock price and shows management's response to recent weakness.
New oral biologics ingredient launched Ashland launched Permexa sodium caprate, an ingredient that helps turn injectable drugs into pills, targeting the fast-growing GLP-1 and metabolic markets. Partners are already testing it. If it wins commercial contracts, it could add a new long-term growth stream.
This is a new product that could drive future revenue growth in Ashland's strongest division, Life Sciences.
Solid sales but profit pressure persists Third-quarter sales rose 7% to $497 million and full-year guidance was reaffirmed, but adjusted EBITDA fell 4% and EPS growth outlook was trimmed due to higher taxes and costs. Weak Specialty Additives and Intermediates continue to weigh on overall profitability.
This explains the underlying business performance that both supports and limits the stock, balancing the positive sale and buyback news.

Latest28 Jul – 25 Sep 2026

▲3

Ashland's sale process advances as buyback and new product offset weak additives

Takeover bids now being collected Ashland is collecting takeover bids this month, with Apollo, Carlyle and others interested. Activist pressure has pushed the company toward a possible sale, and reports suggest a deal could value shares well above recent levels. This keeps a buyout premium in the stock.
The sale process is the biggest force behind ASH's price right now, directly tied to activist pressure and reported bid interest.
New $1 billion buyback doubles prior plan Ashland announced a new $1 billion share repurchase plan, twice its previous authorization. Buying back stock can support the share price by reducing the number of shares and signaling management's confidence, even as the stock had slipped recently.
The buyback is a fresh capital-return action that directly supports the stock price and shows management's response to recent weakness.
New oral biologics ingredient launched Ashland launched Permexa sodium caprate, an ingredient that helps turn injectable drugs into pills, targeting the fast-growing GLP-1 and metabolic markets. Partners are already testing it. If it wins commercial contracts, it could add a new long-term growth stream.
This is a new product that could drive future revenue growth in Ashland's strongest division, Life Sciences.
Solid sales but profit pressure persists Third-quarter sales rose 7% to $497 million and full-year guidance was reaffirmed, but adjusted EBITDA fell 4% and EPS growth outlook was trimmed due to higher taxes and costs. Weak Specialty Additives and Intermediates continue to weigh on overall profitability.
This explains the underlying business performance that both supports and limits the stock, balancing the positive sale and buyback news.

Ecolab Inc (ECL)

Q3 202619 Jun – 18 Aug 2026

▲3

Ecolab bets $4.75B on AI data-center cooling, raises outlook

Ecolab closes $4.75B CoolIT acquisition, expanding AI data-center cooling Ecolab completed its purchase of CoolIT Systems, adding liquid cooling hardware (cold plates, coolant units) to its water-treatment chemicals. Management expects the combined High-Tech platform to grow over 25% a year and reach $4 billion in sales by 2030, with 25% operating margins. This opens a fast-growing AI infrastructure market, supporting a higher long-term growth story and stock price.
The deal is the period's biggest strategic move, directly adding a high-growth AI business that can lift future sales and profits.
Ecolab raises 2026 profit forecast on double-digit EPS growth Second-quarter sales rose 10% to $4.42 billion, organic growth accelerated to 5%, and adjusted EPS climbed 11% to $2.09. Ecolab nudged up its full-year adjusted EPS outlook and expects second-half organic growth of 6-7%. Improved pricing, including an energy surcharge, helped offset rising costs, signaling the core business is healthy and supporting the stock.
The raised guidance and accelerating organic growth show the base business is performing well, a key positive for the share price.
Data-center water treatment market projected to grow 12.3% yearly to $5.9B by 2031 A new report forecasts the global data-center water and wastewater treatment equipment market will nearly double from $3.3 billion in 2026 to $5.9 billion by 2031. Ecolab is named a leading player. This growing market, driven by data-center construction and cooling-water needs, gives Ecolab a long runway for its water-treatment chemicals and services.
It confirms a large, growing addressable market for Ecolab's existing data-center water treatment offerings, supporting future revenue growth.
Rising commodity costs and higher debt after acquisition pressure margins Management expects commodity costs to rise at a high single-digit rate starting in Q2 2026, which could squeeze margins. Also, total debt jumped to $13.18 billion after the CoolIT deal, raising net interest expense to $73.1 million. These cost and leverage headwinds are a real counterweight to the growth story and could weigh on near-term profits.
It highlights the main risks—cost inflation and increased debt—that could offset the positive growth drivers and cap stock gains.

July 202619 Jun – 18 Aug 2026

▲3

Ecolab bets $4.75B on AI data-center cooling, raises outlook

Ecolab closes $4.75B CoolIT acquisition, expanding AI data-center cooling Ecolab completed its purchase of CoolIT Systems, adding liquid cooling hardware (cold plates, coolant units) to its water-treatment chemicals. Management expects the combined High-Tech platform to grow over 25% a year and reach $4 billion in sales by 2030, with 25% operating margins. This opens a fast-growing AI infrastructure market, supporting a higher long-term growth story and stock price.
The deal is the period's biggest strategic move, directly adding a high-growth AI business that can lift future sales and profits.
Ecolab raises 2026 profit forecast on double-digit EPS growth Second-quarter sales rose 10% to $4.42 billion, organic growth accelerated to 5%, and adjusted EPS climbed 11% to $2.09. Ecolab nudged up its full-year adjusted EPS outlook and expects second-half organic growth of 6-7%. Improved pricing, including an energy surcharge, helped offset rising costs, signaling the core business is healthy and supporting the stock.
The raised guidance and accelerating organic growth show the base business is performing well, a key positive for the share price.
Data-center water treatment market projected to grow 12.3% yearly to $5.9B by 2031 A new report forecasts the global data-center water and wastewater treatment equipment market will nearly double from $3.3 billion in 2026 to $5.9 billion by 2031. Ecolab is named a leading player. This growing market, driven by data-center construction and cooling-water needs, gives Ecolab a long runway for its water-treatment chemicals and services.
It confirms a large, growing addressable market for Ecolab's existing data-center water treatment offerings, supporting future revenue growth.
Rising commodity costs and higher debt after acquisition pressure margins Management expects commodity costs to rise at a high single-digit rate starting in Q2 2026, which could squeeze margins. Also, total debt jumped to $13.18 billion after the CoolIT deal, raising net interest expense to $73.1 million. These cost and leverage headwinds are a real counterweight to the growth story and could weigh on near-term profits.
It highlights the main risks—cost inflation and increased debt—that could offset the positive growth drivers and cap stock gains.

Latest19 Jun – 18 Aug 2026

▲3

Ecolab bets $4.75B on AI data-center cooling, raises outlook

Ecolab closes $4.75B CoolIT acquisition, expanding AI data-center cooling Ecolab completed its purchase of CoolIT Systems, adding liquid cooling hardware (cold plates, coolant units) to its water-treatment chemicals. Management expects the combined High-Tech platform to grow over 25% a year and reach $4 billion in sales by 2030, with 25% operating margins. This opens a fast-growing AI infrastructure market, supporting a higher long-term growth story and stock price.
The deal is the period's biggest strategic move, directly adding a high-growth AI business that can lift future sales and profits.
Ecolab raises 2026 profit forecast on double-digit EPS growth Second-quarter sales rose 10% to $4.42 billion, organic growth accelerated to 5%, and adjusted EPS climbed 11% to $2.09. Ecolab nudged up its full-year adjusted EPS outlook and expects second-half organic growth of 6-7%. Improved pricing, including an energy surcharge, helped offset rising costs, signaling the core business is healthy and supporting the stock.
The raised guidance and accelerating organic growth show the base business is performing well, a key positive for the share price.
Data-center water treatment market projected to grow 12.3% yearly to $5.9B by 2031 A new report forecasts the global data-center water and wastewater treatment equipment market will nearly double from $3.3 billion in 2026 to $5.9 billion by 2031. Ecolab is named a leading player. This growing market, driven by data-center construction and cooling-water needs, gives Ecolab a long runway for its water-treatment chemicals and services.
It confirms a large, growing addressable market for Ecolab's existing data-center water treatment offerings, supporting future revenue growth.
Rising commodity costs and higher debt after acquisition pressure margins Management expects commodity costs to rise at a high single-digit rate starting in Q2 2026, which could squeeze margins. Also, total debt jumped to $13.18 billion after the CoolIT deal, raising net interest expense to $73.1 million. These cost and leverage headwinds are a real counterweight to the growth story and could weigh on near-term profits.
It highlights the main risks—cost inflation and increased debt—that could offset the positive growth drivers and cap stock gains.